The invention relates to a TRPM8 modulator for achieving a cooling effect on the skin or a mucous membrane.

Caffeic Acid, L-DOPA, and D-DOPA and prodrugs thereof for treating a disease, condition, or disorder associated with excess glutamate carboxypeptidase II (GCP-II) are disclosed.

Caffeic Acid, L-DOPA, and D-DOPA and prodrugs thereof for treating a disease, condition, or disorder associated with excess glutamate carboxypeptidase II (GCP-II) are disclosed.

Amido compounds are disclosed that have a formula represented by the following:

##STR00001##

and wherein n1, n2, R.sup.1a, R.sup.1b, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.

It belongs to the field of medicinal chemistry, in particular discloses anti-inflammatory and analgesic compounds and use thereof, the compounds of the present invention are compounds, isomers or pharmaceutically acceptable salts as shown in formula (I) or formula (II); the compounds have significant curative effect on gouty arthritis in rats, and have excellent anti-inflammatory factor effect; therefore, the compounds have potential application prospects in anti-inflammatory and analgesic drugs, especially in anti-acute gouty arthritis drugs, anti-rheumatoid arthritis drugs, drugs to reduce inflammatory factors, drugs to treat inflammatory storm or coronavirus pneumonia.

It belongs to the field of medicinal chemistry, in particular discloses anti-inflammatory and analgesic compounds and use thereof, the compounds of the present invention are compounds, isomers or pharmaceutically acceptable salts as shown in formula (I) or formula (II); the compounds have significant curative effect on gouty arthritis in rats, and have excellent anti-inflammatory factor effect; therefore, the compounds have potential application prospects in anti-inflammatory and analgesic drugs, especially in anti-acute gouty arthritis drugs, anti-rheumatoid arthritis drugs, drugs to reduce inflammatory factors, drugs to treat inflammatory storm or coronavirus pneumonia.

The present disclosure provides novel 4-substituted-phenyl acetamide and arylurea derivatives that act as agonists against GPR88. The compounds of the present disclosure are believed to be useful for the treatment of diseases and conditions caused by physiological processes implicating the orphan receptor GPR88, including diverse brain and behavioral functions such as cognition, mood, movement control, and reward-based learning. GPR88 is emerging as a novel drug target for central nervous system disorders including schizophrenia, Parkinson's disease, anxiety, and addiction. One particular indication for which GPR88 agonists hold promise is alcohol use disorder (AUD).

The present disclosure provides novel 4-substituted-phenyl acetamide and arylurea derivatives that act as agonists against GPR88. The compounds of the present disclosure are believed to be useful for the treatment of diseases and conditions caused by physiological processes implicating the orphan receptor GPR88, including diverse brain and behavioral functions such as cognition, mood, movement control, and reward-based learning. GPR88 is emerging as a novel drug target for central nervous system disorders including schizophrenia, Parkinson's disease, anxiety, and addiction. One particular indication for which GPR88 agonists hold promise is alcohol use disorder (AUD).

The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.